Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options.

Gastaldelli A, Cusi K.

JHEP Rep. 2019 Jul 19;1(4):312-328. doi: 10.1016/j.jhepr.2019.07.002. eCollection 2019 Oct. Review.

2.

Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?

Budd J, Cusi K.

Am J Med. 2020 Feb 1. pii: S0002-9343(20)30100-5. doi: 10.1016/j.amjmed.2020.01.007. [Epub ahead of print] Review.

PMID:
32017891
3.

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes.

Cusi K.

Diabetes Care. 2020 Feb;43(2):275-279. doi: 10.2337/dci19-0064. No abstract available.

PMID:
31959644
4.

Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy.

Sattari M, Bril F, Egerman R, Kalavalapalli S, Cusi K.

J Investig Med. 2019 Dec 17. pii: jim-2019-001186. doi: 10.1136/jim-2019-001186. [Epub ahead of print]

PMID:
31852748
5.

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC.

J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]

PMID:
31697972
6.

Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

Bril F, McPhaul MJ, Caulfield MP, Clark VC, Soldevilla-Pico C, Firpi-Morell RJ, Lai J, Shiffman D, Rowland CM, Cusi K.

Diabetes Care. 2020 Feb;43(2):290-297. doi: 10.2337/dc19-1071. Epub 2019 Oct 11.

PMID:
31604692
7.

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.

Bril F, Barb D, Lomonaco R, Lai J, Cusi K.

J Hepatol. 2020 Mar;72(3):401-410. doi: 10.1016/j.jhep.2019.09.018. Epub 2019 Oct 4.

PMID:
31589891
8.

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.

Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, Suman A, Orsak BK, Hecht J, Cusi K.

Diabetes Care. 2019 Aug;42(8):1481-1488. doi: 10.2337/dc19-0167. Epub 2019 May 21.

PMID:
31332029
9.

Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis.

Colomba J, Netedu SR, Lehoux-Dubois C, Coriati A, Boudreau V, Tremblay F, Cusi K, Rabasa-Lhoret R, Leey JA.

PLoS One. 2019 Jul 18;14(7):e0219855. doi: 10.1371/journal.pone.0219855. eCollection 2019.

10.

Nonalcoholic Fatty Liver Disease: The Overlooked Complication of Type 2 Diabetes.

Akshintala D, Chugh R, Amer F, Cusi K.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2019 Jul 9.

11.

Letter to the Editor: "Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content".

Bril F, Cusi K.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5249-5250. doi: 10.1210/jc.2019-00970. No abstract available.

PMID:
31225877
12.

Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes.

Bril F, Leeming DJ, Karsdal MA, Kalavalapalli S, Barb D, Lai J, Rabe M, Cusi K.

Diabetes Care. 2019 Jul;42(7):1348-1351. doi: 10.2337/dc18-2578. Epub 2019 May 21.

PMID:
31221701
13.

Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities.

Fernando HJ, Cohen RA, Gullett JM, Friedman J, Ayzengart A, Porges E, Woods AJ, Gunstad J, Ochoa CM, Cusi K, Gonzalez-Louis R, Donahoo WT.

Obesity (Silver Spring). 2019 Jul;27(7):1099-1106. doi: 10.1002/oby.22508. Epub 2019 May 22.

14.

Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.

Kalavalapalli S, Bril F, Guingab J, Vergara A, Garrett TJ, Sunny NE, Cusi K.

J Endocrinol. 2019 Jun 1;241(3):293-305. doi: 10.1530/JOE-19-0007.

PMID:
31082799
15.

Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.

Cusi K.

Hepatology. 2019 Jun;69(6):2318-2322. doi: 10.1002/hep.30670. Epub 2019 May 13. No abstract available.

PMID:
31006135
16.

Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.

Barb D, Bril F, Kalavalapalli S, Cusi K.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3327-3336. doi: 10.1210/jc.2018-02414.

PMID:
30848827
17.

Re: "Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis" by Mantovani et al. (Thyroid 2018;28:1270-1284).

Bril F, Kadiyala S, Cusi K.

Thyroid. 2019 Mar;29(3):452. doi: 10.1089/thy.2018.0622. Epub 2019 Feb 6. No abstract available.

PMID:
30652529
18.

Effect of all-extremity high-intensity interval training vs. moderate-intensity continuous training on aerobic fitness in middle-aged and older adults with type 2 diabetes: A randomized controlled trial.

Hwang CL, Lim J, Yoo JK, Kim HK, Hwang MH, Handberg EM, Petersen JW, Holmer BJ, Leey Casella JA, Cusi K, Christou DD.

Exp Gerontol. 2019 Feb;116:46-53. doi: 10.1016/j.exger.2018.12.013. Epub 2018 Dec 18.

19.

Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.

Khan RS, Bril F, Cusi K, Newsome PN.

Hepatology. 2019 Aug;70(2):711-724. doi: 10.1002/hep.30429. Epub 2019 Jul 19. Review.

PMID:
30556145
20.

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.

Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR.

Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13584. [Epub ahead of print]

PMID:
30447037
21.

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

Bril F, McPhaul MJ, Caulfield MP, Castille JM, Poynard T, Soldevila-Pico C, Clark VC, Firpi-Morell RJ, Lai J, Cusi K.

J Investig Med. 2019 Feb;67(2):303-311. doi: 10.1136/jim-2018-000864. Epub 2018 Oct 10.

22.

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.

Stefan N, Häring HU, Cusi K.

Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324. doi: 10.1016/S2213-8587(18)30154-2. Epub 2018 Aug 30. Review.

PMID:
30174213
23.
24.

Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.

Portillo-Sanchez P, Bril F, Lomonaco R, Barb D, Orsak B, Bruder JM, Cusi K.

J Diabetes. 2019 Mar;11(3):223-231. doi: 10.1111/1753-0407.12833. Epub 2018 Sep 3.

PMID:
30073778
25.

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis.

Kawaguchi-Suzuki M, Cusi K, Bril F, Gong Y, Langaee T, Frye RF.

Front Pharmacol. 2018 Jul 17;9:752. doi: 10.3389/fphar.2018.00752. eCollection 2018.

26.

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.

Cusi K, Sattar N, García-Pérez LE, Pavo I, Yu M, Robertson KE, Karanikas CA, Haupt A.

Diabet Med. 2018 Oct;35(10):1434-1439. doi: 10.1111/dme.13697. Epub 2018 Jun 22.

PMID:
29869810
27.

Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.

Kalavalapalli S, Bril F, Koelmel JP, Abdo K, Guingab J, Andrews P, Li WY, Jose D, Yost RA, Frye RF, Garrett TJ, Cusi K, Sunny NE.

Am J Physiol Endocrinol Metab. 2018 Aug 1;315(2):E163-E173. doi: 10.1152/ajpendo.00023.2018. Epub 2018 Apr 10.

28.

Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH.

Leey J, Cusi K.

Aliment Pharmacol Ther. 2018 Apr;47(8):1220-1221. doi: 10.1111/apt.14473. No abstract available.

29.

Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Bril F, Millán L, Kalavalapalli S, McPhaul MJ, Caulfield MP, Martinez-Arranz I, Alonso C, Ortiz Betes P, Mato JM, Cusi K.

Diabetes Obes Metab. 2018 Jul;20(7):1702-1709. doi: 10.1111/dom.13285. Epub 2018 Apr 14.

PMID:
29527789
30.

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.

Bril F, Kalavalapalli S, Clark VC, Lomonaco R, Soldevila-Pico C, Liu IC, Orsak B, Tio F, Cusi K.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):558-566.e2. doi: 10.1016/j.cgh.2017.12.001. Epub 2017 Dec 7.

PMID:
29223443
31.

Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.

Sanyal A, Cusi K, Hartman ML, Zhang S, Bastyr EJ 3rd, Bue-Valleskey JM, Chang AM, Haupt A, Jacober SJ, Konrad RJ, Zhang Q, Hoogwerf BJ.

J Investig Med. 2018 Mar;66(3):661-668. doi: 10.1136/jim-2017-000609. Epub 2017 Nov 21.

PMID:
29167192
32.

Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients.

Bril F, Portillo-Sanchez P, Liu IC, Kalavalapalli S, Dayton K, Cusi K.

Diabetes Care. 2018 Jan;41(1):187-192. doi: 10.2337/dc17-1349. Epub 2017 Nov 13.

PMID:
29133343
33.

Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.

Dhir G, Cusi K.

J Investig Med. 2018 Jan;66(1):7-10. doi: 10.1136/jim-2017-000554. Epub 2017 Sep 15. Review.

PMID:
28918389
34.

The Yin and Yang Between Plasma Glucose Levels and Cortisol Replacement Therapy in Schmidt's Syndrome.

Newton CA, Sheehan E, Wyne K, Cusi K, Leey J, Ghayee HK.

J Investig Med High Impact Case Rep. 2017 Jul 6;5(3):2324709617716203. doi: 10.1177/2324709617716203. eCollection 2017 Jul-Sep.

35.

Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.

Barritt AS 4th, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A.

Contemp Clin Trials. 2017 Oct;61:33-38. doi: 10.1016/j.cct.2017.07.015. Epub 2017 Jul 19.

PMID:
28735109
36.

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ.

Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29. Review. No abstract available.

PMID:
28714183
37.

Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.

Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, Cusi K.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2950-2961. doi: 10.1210/jc.2017-00867.

38.

Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.

Kawaguchi-Suzuki M, Bril F, Kalavalapalli S, Cusi K, Frye RF.

Aliment Pharmacol Ther. 2017 Jul;46(1):56-61. doi: 10.1111/apt.14111. Epub 2017 May 3.

39.

Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.

Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A.

Diabetes Obes Metab. 2017 Nov;19(11):1630-1634. doi: 10.1111/dom.12973. Epub 2017 Jun 22.

PMID:
28417532
40.

Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus.

Cusi K.

Gut. 2018 Jul;67(7):1371. doi: 10.1136/gutjnl-2017-313958. Epub 2017 Apr 13. No abstract available.

PMID:
28408383
41.

Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit.

Bril F, Cusi K.

Hepatology. 2017 Jul;66(1):296-297. doi: 10.1002/hep.29150. Epub 2017 May 26. No abstract available.

PMID:
28295426
42.

Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.

Bril F, Cusi K.

Diabetes Care. 2017 Mar;40(3):419-430. doi: 10.2337/dc16-1787. Review.

PMID:
28223446
43.

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis.

Bril F, Cusi K.

Ann Intern Med. 2017 Feb 7;166(3):230. doi: 10.7326/L16-0629. No abstract available.

PMID:
28166556
44.

Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.

Williams RN, Filozof C, Goldstein BJ, Cusi K.

Clin Pharmacol Ther. 2017 Apr;101(4):444-446. doi: 10.1002/cpt.560. Epub 2016 Dec 29.

45.

Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.

Sunny NE, Bril F, Cusi K.

Trends Endocrinol Metab. 2017 Apr;28(4):250-260. doi: 10.1016/j.tem.2016.11.006. Epub 2016 Dec 13. Review.

PMID:
27986466
46.

Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.

Bril F, Barb D, Portillo-Sanchez P, Biernacki D, Lomonaco R, Suman A, Weber MH, Budd JT, Lupi ME, Cusi K.

Hepatology. 2017 Apr;65(4):1132-1144. doi: 10.1002/hep.28985. Epub 2017 Feb 25.

PMID:
27981615
47.

Reply to "statins and non-alcoholic steatohepatitis".

Barb D, Cusi K.

Metabolism. 2017 Jan;66:e3-e5. doi: 10.1016/j.metabol.2016.10.004. Epub 2016 Oct 24. No abstract available.

PMID:
27865560
48.

Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.

Bril F, Cusi K.

Endocrinol Metab Clin North Am. 2016 Dec;45(4):765-781. doi: 10.1016/j.ecl.2016.06.005. Epub 2016 Oct 4. Review.

PMID:
27823604
49.

Prediabetes: A Worldwide Epidemic.

Edwards CM, Cusi K.

Endocrinol Metab Clin North Am. 2016 Dec;45(4):751-764. doi: 10.1016/j.ecl.2016.06.007. Epub 2016 Oct 2. Review.

PMID:
27823603
50.

Diabetes medications improve cardiovascular outcomes: the paradigm shifts.

Cusi K.

Curr Opin Lipidol. 2016 Dec;27(6):633-635. No abstract available.

PMID:
27805974

Supplemental Content

Support Center